Your browser doesn't support javascript.
loading
Combined glucocorticoids and cyclophosphamide in the treatment of Graves' ophthalmopathy: a systematic review and meta-analysis.
Xiang, Qilang; Yang, Mengling; Luo, Wenxuan; Cao, Yuzi; Shuai, Shiquan; Wei, Xin; Xiong, Anji.
Afiliación
  • Xiang Q; Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
  • Yang M; School of Medicine, Chongqing University, Chongqing, China.
  • Luo W; Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College/Nanchong Hospital of Beijing Anzhen Hospital Capital Medical University, Nanchong, China.
  • Cao Y; Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College/Nanchong Hospital of Beijing Anzhen Hospital Capital Medical University, Nanchong, China.
  • Shuai S; Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College/Nanchong Hospital of Beijing Anzhen Hospital Capital Medical University, Nanchong, China.
  • Wei X; Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China. weixin_1982@163.com.
  • Xiong A; Department of Rheumatology and Immunology, Nanchong Central Hospital, The Affiliated Nanchong Central Hospital of North Sichuan Medical College/Nanchong Hospital of Beijing Anzhen Hospital Capital Medical University, Nanchong, China. xionganji@126.com.
BMC Endocr Disord ; 24(1): 12, 2024 Jan 26.
Article en En | MEDLINE | ID: mdl-38273269
ABSTRACT

PURPOSE:

To evaluate the efficacy and safety of combined glucocorticoids (GCs) and cyclophosphamide (CYC) treatment in Graves' ophthalmopathy (GO).

METHODS:

We searched PubMed, Embase, Cochrane Library, and four Chinese databases (Chinese National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), WanFang, and SinoMed) for any published randomized controlled trials (RCTs) produced from inception to December 1, 2023. Articles obtained using appropriate keywords were selected independently by two reviewers according to the established inclusion and exclusion criteria.

FINDINGS:

We retrieved 1120 records which were eventually reduced to 13 RCTs which were then included in this evaluation. Pooled results indicated that the experimental group (CYC/GCs) showed a higher response rate than control group (GCs or negative control) (RR 1.27; 95% confidence interval 1.19 to 1.37). The subgroup analysis showed that the difference in response rates among treatment protocols (CYC/P, CYC/MPS, CYC/DEX) was not statistically significant (p = 0.23). IMPLICATIONS The combination of GCs and CYC could be recommended as a therapeutic option for GO, especially in patients who experience recurrence after a withdrawal GCs, have a poor response to GCs, or cannot obtain monoclonal antibody agents for various reasons.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oftalmopatía de Graves / Glucocorticoides Tipo de estudio: Clinical_trials / Guideline / Systematic_reviews Límite: Humans País/Región como asunto: Asia Idioma: En Revista: BMC Endocr Disord Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oftalmopatía de Graves / Glucocorticoides Tipo de estudio: Clinical_trials / Guideline / Systematic_reviews Límite: Humans País/Región como asunto: Asia Idioma: En Revista: BMC Endocr Disord Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido